Not Developing Any New Drugs Could Be EQRx’s Biggest Innovation
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
Prostate Cancer News
PROSTATE CANCER ADVISOR
Prostate Cancer News
Prostate MRI Improves Confirmatory Biopsy Sensitivity
MRI-guided confirmatory prostate biopsies more accurately detects grade progression among men on active surveillance for prostate cancer compared with TRUS-guided systematic biopsies alone.
Salvage Radiotherapy Called a Viable Option for Recurrent Prostate Cancer
The authors of new review say the results of the JCOG0401 trial suggest that standard hormonal therapy alone vs salvage radiotherapy is not an appropriate management strategy for recurrence after radical prostatectomy.
10-Year Outcomes Similar for H-IMRT, C-IMRT in Prostate Cancer
10-year cumulative incidence of biochemical and/or clinical disease failure no different with C-, H-IMRT.
Exploring the DNA Methylome in mCRPC Through NGS of Plasma DNA Specimens
An understanding of the tumor methylome can provide information on gene regulation in different cancers.
“Medical Distancing” May Help Protect Cancer Patients From Exposure to COVID-19
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
Federal Ruling Puts Pressure on Clinical Trial Sponsors to Post Data
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
Combining MRI-Targeted, Systematic Biopsy Appears Best for PCa Detection
In a study, 8.8% of clinically relevant prostate cancers detected by systematic biopsy were missed by MRI-targeted biopsy.
Docetaxel Use in High-Risk Prostate Cancer: New Long-Term Data
There was a small beneficial effect of adding docetaxel to androgen suppression and radiotherapy, a follow-up study showed.
First Human Clinical Trial in US to Test the Use of CRISPR-Modified T Cells in Cancer Answers Vital Questions
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
New Study Supports PSA-Stratified Prostate Cancer Screening
Less intensive PSA screening in men with low PSA levels can substantially reduce unnecessary testing, according to investigators.
Canned, Cooked Tomatoes May Cut Prostate Cancer Risk
Consumption of canned and cooked tomatoes 5 to 6 times a week was significantly associated with a 28% lower risk of prostate cancer compared with no consumption of these foods, a study found.
Improving Cancer Pain Management Amid the Opioid Crisis
Research into opioid alternatives for cancer-related pain has stalled, however substance use disorders remain problematic.
A New Trend in Drug Development: Leveraging Data from Expanded Access
Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.
Evidence Suggests B Cells Play a Role in Immunotherapy Response
New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.
Prostate Cancer Surgical Approach Not a Factor in Treatment Decision Regret
Type of surgical approach to radical prostatectomy—robot-assisted vs open procedure—is not associated with a patient’s intermediate-term decision regret, according to a recent study.
Functional Outcomes Similar Across Localized Prostate Cancer Treatments
However, incontinence and sexual function are worse five years following prostatectomy.
The Questionable Practice That Permeates Oncology Clinical Trials
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Overall Survival in mCRPC Cases Linked to Number of Radium-223 Doses
Men with metastatic castration-resistant prostate cancer with predominantly bone metastases who receive more than 4 dose of radium-223 have significantly improved overall survival than those who receive 4 or fewer doses, a study found.
Radium-223 Plus Sipuleucel-T Found to Slow mCRPC Progression
Combining sipuleucel-T and radium-223 improves progression-free survival among men with metastatic castration-resistant prostate cancer (mCRPC) who have bone predominant metastases, a randomized phase 2 study found.
Want to read more?
Please login or register first to view this content.
